Cargando…

Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by an autoantibody-mediated deficiency in ADAMTS13. In healthy individuals, ADAMTS13 has a folded conformation in which the central spacer (S) domain interacts with the C-terminal CUB domains. We recently showed that ADAMTS13 adopt...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Waele, Laure, Curie, Alexandre, Kangro, Kadri, Tellier, Edwige, Kaplanski, Gilles, Männik, Andres, Tersteeg, Claudia, Joly, Bérangère S., Coppo, Paul, Veyradier, Agnès, De Meyer, Simon F., Roose, Elien, Vanhoorelbeke, Karen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Stimulus Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579268/ https://www.ncbi.nlm.nih.gov/pubmed/34559219 http://dx.doi.org/10.1182/bloodadvances.2021004971

Ejemplares similares

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura
por: Kangro, Kadri, et al.
Publicado: (2020)

ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
por: Joly, Bérangère S., et al.
Publicado: (2022)

Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay
por: Bonnez, Quintijn, et al.
Publicado: (2023)

TTP: From empiricism for an enigmatic disease to targeted molecular therapies
por: Graça, Nuno A. G., et al.
Publicado: (2022)

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
por: Graça, Nuno A. G., et al.
Publicado: (2019)

Caplacizumab as frontline therapy in addition to standard treatment in iTTP
por: Cid, Joan, et al.
Publicado: (2022)

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients
por: Schelpe, An-Sofie, et al.
Publicado: (2019)

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase
por: Westwood, John Paul, et al.
Publicado: (2022)

Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020)

PROFILE: Early-Stage Researchers Advancing Insights in TTP Through a Unique PhD Track
por: Vanhoorelbeke, Karen, et al.
Publicado: (2018)

Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay
por: Beranger, Nicolas, et al.
Publicado: (2020)

P1598: UTILITY OF ‘OPEN/CLOSED’ ADAMTS13 IN MONITORING IMMUNE TTP
por: Prasannan, Nithya, et al.
Publicado: (2023)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012)

Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura
por: Deforche, Louis, et al.
Publicado: (2016)

Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severity
por: Tellier, Edwige, et al.
Publicado: (2022)

Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19
por: Guervilly, Christophe, et al.
Publicado: (2021)

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection
por: Fang, Fei, et al.
Publicado: (2022)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE
por: Subhan, Maryam, et al.
Publicado: (2023)

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
por: Sakai, Kazuya, et al.
Publicado: (2022)

Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?
por: Mir, Tajamul H.
Publicado: (2021)

Anti-ADAMTS13 Antibodies and a Novel Heterozygous p.R1177Q Mutation in a Case of Pregnancy-Onset Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Roose, Elien, et al.
Publicado: (2018)

The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review
por: Joseph, Adrien, et al.
Publicado: (2023)

An Imperfect Marker: SLE and TTP-Like MAHA Without Low ADAMTS13
por: Chiruvolu, Neha V., et al.
Publicado: (2021)

The SARS-CoV-2 receptor-binding domain preferentially recognizes blood group A
por: Wu, Shang-Chuen, et al.
Publicado: (2021)

Impact of sickle cell trait on morbidity and mortality from SARS-CoV-2 infection
por: Merz, Lauren E., et al.
Publicado: (2021)

IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2022)

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP
por: Busca, Alessandro, et al.
Publicado: (2022)

A novel class of ZNF384 aberrations in acute leukemia
por: Zaliova, Marketa, et al.
Publicado: (2021)

Rational biomarker development for the early and minimally invasive monitoring of AML
por: Abdelhamed, Sherif, et al.
Publicado: (2021)

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes
por: Gurnari, Carmelo, et al.
Publicado: (2022)

JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β
por: Yan, Yuhan, et al.
Publicado: (2022)

Worse outcome and distinct mutational pattern in follicular lymphoma with anti-HBc positivity
por: Fernández-Rodríguez, Concepción, et al.
Publicado: (2022)

Coevolving JAK2(V617F+)relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
por: Penter, Livius, et al.
Publicado: (2021)

Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS
por: Syrykh, Charlotte, et al.
Publicado: (2021)

Single-cell polyfunctional proteomics of CD4 cells from patients with AML predicts responses to anti–PD-1–based therapy
por: Abbas, Hussein A., et al.
Publicado: (2021)

Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination
por: Lee, Agnes Y. Y., et al.
Publicado: (2022)

RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea
por: Zouali, Habib, et al.
Publicado: (2022)

Day 30 SUV(max) predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
por: Al Zaki, Ajlan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8mshi0br6ehpg96g8knms569am